^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Follicular Lymphoma
    Regimen:R-CVP (cyclophosphamide + + Rituxan (rituximab) + vincristine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    01/20/2021
    Excerpt:
    Follicular Lymphoma: FIRST-LINE THERAPY…Preferred Regimens…CVP (cyclophosphamide, vincristine, prednisone) + Obinutuzumab or rituximab
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    11/26/2020
    Excerpt:
    Consensus-driven recommendations- For stage III/IV FL with high tumor burden and > 65 years and < 65 years immunoCHT such as...R-CVP (cyclophosphamide, vincristine, prednisolone) [I,A].
    DOI:
    10.1016/j.annonc.2020.11.008